The Anti-Diabetes Drugs market in Southern Europe has witnessed significant growth in recent years.
Customer preferences: The increasing prevalence of diabetes in Southern Europe has led to a surge in demand for anti-diabetes drugs. Patients are increasingly opting for drugs that offer better glycemic control and fewer side effects, leading to a shift towards newer and more innovative drugs.
Trends in the market: Spain, Italy, and Greece are the largest markets for anti-diabetes drugs in Southern Europe. The market is dominated by big pharma companies, with Novo Nordisk, Sanofi, and Eli Lilly being the major players. The market has witnessed a shift towards GLP-1 receptor agonists and SGLT-2 inhibitors, which offer better glycemic control and cardiovascular benefits. Biosimilars have also gained popularity in the region, owing to their cost-effectiveness.
Local special circumstances: Southern Europe has a high prevalence of diabetes, owing to factors such as an aging population, sedentary lifestyle, and unhealthy dietary habits. The region also has a high prevalence of obesity, which is a major risk factor for diabetes. The healthcare systems in Southern Europe are publicly funded, and the governments have been taking initiatives to improve diabetes management and increase access to anti-diabetes drugs.
Underlying macroeconomic factors: The economic crisis in Southern Europe has led to a decrease in healthcare spending, which has affected the anti-diabetes drugs market. However, the market has been resilient and has continued to grow, owing to the high prevalence of diabetes in the region. The increasing focus on preventative healthcare and the adoption of innovative drugs are expected to drive the market in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
